During a Tuesday morning plenary session, Miriam Merad, MD, PhD, and a panel of cancer immunologists discussed some of the latest discoveries that are driving advances in cancer immunology research and therapeutic development.
During a Monday symposium, three researchers, including Quynh-Thu Le, MD, explored the potential of novel strategies to enhance the efficacy of radiation therapy in solid cancer at the individual level, and how these emerging therapies could help clinicians address the challenge of predicting therapeutic response.
Researchers reported promising results from five studies, including the first cancer vaccine trial to demonstrate clinical benefit in melanoma, which was reported by Jeffrey S. Weber, MD, PhD, during the first clinical trials plenary session at the Annual Meeting.
In the second clinical trials plenary session at the Annual Meeting, positive results were reported from four more studies. Timothy A. Yap, MD, PhD, reported on a study that provides the first clinical proof-of-concept for effectively drugging the Hippo-YAP pathway.
During her presidential address Sunday evening, AACR President Lisa M. Coussens, PhD, FAACR, compared advances in cancer research to her own career journey and shared her hopes for the future of cancer research.
The last five forum sessions at the Annual Meeting will examine topics including biostatistics in clinical research, engaging diverse communities in clinical trials, and overcoming cancer workforce challenges.
An expert panel of cancer researchers, including Tomi Akinyemiju, PhD, showcased cutting-edge research in diverse fields of study that is opening up new frontiers in all areas of cancer research, from basic science and drug discovery to population science and health equity.